



Future GLP-1 Medications: Pipeline Intelligence Report

Evidence-informed overview of the five investigational weight-loss medications most likely to reach commercial availability between 2026 and 2029.

DawaMed.org · Educational Clinical Guide
Content reviewed against published clinical literature

Published: May 2026
For educational use only

Overview

KEY TAKEAWAYS

- ✓ Five investigational GLP-1-class medications are in Phase 3 trials as of 2026
- ✓ Retatrutide (triple agonist) has demonstrated the highest Phase 2 weight loss (~24%)
- ✓ CagriSema (GLP-1 + amylin) showed ~22.7% in Phase 3 — confirming Phase 2 data
- ✓ Orforglipron would be the first practical daily oral GLP-1 pill for obesity
- ✓ No investigational medication has FDA approval — all remain in active development
- ✓ Timeline estimates are subject to regulatory review outcomes

RETATRUTIDE

~24%

Phase 2 · Triple Agonist · Eli Lilly

CAGRISEMA

~22.7%

Phase 3 · GLP-1 + Amylin · Novo Nordisk

ORFORGLIPRON

~14.7%

Phase 2 · Oral Daily Pill · Eli Lilly

CAGRISEMA EST. APPROVAL

2026-2027

NDA submission planned

RETATRUTIDE EST. APPROVAL

2027-2028

Phase 3 underway

ORFORGLIPRON EST. APPROVAL

2026-2027

Phase 3 underway

Retatrutide

Developer: Eli Lilly · **Mechanism:** Triple agonist (GLP-1, GIP, glucagon) · **Status:** Phase 3

Phase 2 data demonstrated ~24.2% average weight loss at 48 weeks (12 mg dose). The TRIUMPH Phase 3 program will confirm or modify this estimate. Estimated approval 2027–2028.

CagriSema

Developer: Novo Nordisk · **Mechanism:** GLP-1 agonist + Amylin analogue · **Status:** Phase 3 Complete

REDEFINE 1 Phase 3 data: ~22.7% average weight loss at 68 weeks. NDA submission anticipated 2025–2026; potential approval 2026–2027.

Orforglipron

Developer: Eli Lilly · **Mechanism:** Oral non-peptide GLP-1 agonist · **Status:** Phase 3

First small-molecule GLP-1 agonist for obesity — no injection required, no food restrictions. Phase 2: ~14.7% average weight loss at 36 weeks. Estimated approval 2026–2027.

Educational use only. This document was generated by DawaMed.org for informational purposes and does not constitute medical advice, a diagnosis, or a treatment recommendation. Always consult a licensed clinician before making medical decisions. Data sourced from published clinical trial results and FDA labeling current as of 2025–2026.

Sources & References

Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023.

Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg. Lancet 2021.

Wharton S et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. NEJM 2023.